AENEAS:阿美替尼对比吉非替尼一线治疗EGFR外显子19缺失或L858R突变的局部晚期或转移性非小细胞肺癌的随机III期试验
AENEAS是一项在中国53个中心开展的双盲III期随机试验,429例未经治疗的局部晚期或转移性EGFR突变非小细胞肺癌患者按1:1随机接受阿美替尼110 mg或吉非替尼250 mg每日一次口服。阿美替尼组中位无进展生存期显著长于吉非替尼组(19.3个月 vs 9.9个月;HR 0.46,95%CI 0.36-0.60;P<.0001)。两组客观缓解率和疾病控制率相似,≥3级不良事件发生率相近,阿美替尼组皮疹和腹泻发生率较低。
要点
- 阿美替尼组中位PFS为19.3个月,吉非替尼组为9.9个月,HR 0.46(95%CI 0.36-0.60;P<.0001)。
- 两组客观缓解率(73.8% vs 72.1%)和疾病控制率(93.0% vs 96.7%)相似。
- ≥3级不良事件发生率阿美替尼组36.4%、吉非替尼组35.8%;皮疹和腹泻(任何级别)阿美替尼组较低。
核心结论
- 阿美替尼是一种耐受良好的第三代EGFR酪氨酸激酶抑制剂,可作为EGFR突变非小细胞肺癌一线治疗的选择。
研究设计与样本
- 双盲III期随机对照试验,在中国53个中心开展,患者按1:1随机接受阿美替尼110 mg或吉非替尼250 mg每日一次口服。
- 共纳入429例未经治疗的局部晚期或转移性EGFR突变非小细胞肺癌患者。
- 主要终点为研究者评估的无进展生存期。
主要发现
- 阿美替尼组中位PFS为19.3个月(95%CI 17.8-20.8),吉非替尼组为9.9个月(95%CI 8.3-12.6),HR 0.46(95%CI 0.36-0.60;P<.0001)。
- 阿美替尼组客观缓解率73.8%,吉非替尼组72.1%;疾病控制率分别为93.0%和96.7%。
- 阿美替尼组中位缓解持续时间为18.1个月(95%CI 15.2-不可评估),吉非替尼组为8.3个月(95%CI 6.9-11.1)。
- ≥3级不良事件(任何原因)发生率阿美替尼组36.4%,吉非替尼组35.8%。
- 皮疹(任何级别)发生率阿美替尼组23.4%,吉非替尼组41.4%;腹泻(任何级别)发生率分别为16.4%和35.8%。
关键数值与推荐
- 阿美替尼组中位PFS 19.3个月(95%CI 17.8-20.8)vs 吉非替尼组9.9个月(95%CI 8.3-12.6),HR 0.46(95%CI 0.36-0.60;P<.0001)。
- 客观缓解率阿美替尼组73.8% vs 吉非替尼组72.1%;疾病控制率阿美替尼组93.0% vs 吉非替尼组96.7%。
- 中位缓解持续时间阿美替尼组18.1个月(95%CI 15.2-不可评估)vs 吉非替尼组8.3个月(95%CI 6.9-11.1)。
- ≥3级不良事件发生率阿美替尼组36.4% vs 吉非替尼组35.8%。
- 皮疹(任何级别)阿美替尼组23.4% vs 吉非替尼组41.4%;腹泻(任何级别)阿美替尼组16.4% vs 吉非替尼组35.8%。
临床怎么用
- 原文结论认为阿美替尼是一种耐受良好的第三代EGFR酪氨酸激酶抑制剂,可作为EGFR突变非小细胞肺癌一线治疗的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768). METHODS: Patients at 53 sites in China were randomly assigned 1:1 to receive either aumolertinib (110 mg) or gefitinib (250 mg) once daily. The primary end point was progression-free survival (PFS) per investigator assessment. RESULTS: A total of 429 patients who were naïve to treatment for locally advanced or metastatic NSCLC were enrolled. PFS was significantly longer with aumolertinib compared with gefitinib (hazard ratio, 0.46; 95% CI, 0.36 to 0.60; P < .0001). The median PFS with aumolertinib was 19.3 months (95% CI, 17.8 to 20.8) versus 9.9 months with gefitinib (95% CI, 8.3 to 12.6). Objective response rate and disease control rate were similar in the aumolertinib and gefitinib groups (objective response rate, 73.8% and 72.1%, respectively; disease control rate, 93.0% and 96.7%, respectively). The median duration of response was 18.1 months (95% CI, 15.2 to not applicable) with aumolertinib versus 8.3 months (95% CI, 6.9 to 11.1) with gefitinib. Adverse events of grade ≥ 3 severity (any cause) were observed in 36.4% and 35.8% of patients in the aumolertinib and gefitinib groups, respectively. Rash and diarrhea (any grade) were observed in 23.4% and 16.4% of patients who received aumolertinib compared with 41.4% and 35.8% of those who received gefitinib, respectively. CONCLUSION: Aumolertinib is a well-tolerated third-generation epidermal growth factor receptor tyrosine kinase inhibitor that could serve as a treatment option for EGFR-mutant NSCLC in the first-line setting.
引用
- Lu S, Dong X, Jian H, et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022. PMID: 35580297. doi:10.1200/JCO.21.02641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。